Vasectomy Procedures
Customize your policy alerts
Sign up for Aetna Policy 0027 alerts
Get alerted when Policy 0027 changes without checking for updates manually.
Monitor payer policy activity
Defines Aetna's coverage stance for vasectomy-related procedures, including medical necessity for vasectomy reversal for post-vasectomy pain syndrome and procedures considered experimental/investigational. Applies to Aetna members subject to the payer's benefit rules.
No material clinical or coverage changes in this revision.
Coverage Criteria for Vasectomy-related Procedures
Vasectomy reversal for post-vasectomy pain syndrome
Covered when ALL of the following are met
Per policy medical necessity statement; document (UpToDate) identifies NSAIDs and warm baths as first-line and nerve blocks/steroid injections as next-line treatments before considering surgery.
Surgical treatment of PVPS (general criteria)
Consider surgical intervention for PVPS after ALL of the following are met:
Based on retrospective series and reviews; timing to proceed to surgery is individualized and no standardized protocols exist.
Indications for vasectomy reversal or other surgical interventions for PVPS
Surgical interventions (including vasectomy reversal) for PVPS are considered after failure of conservative therapies and after exclusion of other causes of pain.
Document emphasizes individualized decision-making; orchiectomy is a last-resort option with high rates of persistent pain in some series; no standardized timelines for conservative therapy duration are specified.
Aetna considers several procedures experimental and investigational because peer-reviewed evidence is inadequate to establish effectiveness. Examples explicitly listed in the policy include endoscopic vasectomy and device- or clip-based occlusion methods such as the implantable vas deferens ligation clip (Vasclip). The policy names other novel occlusion approaches (e.g., Pro‑Vas occlusion) and percutaneous injection/occlusion techniques as investigational as well. These procedures are not supported as medically necessary due to limited clinical data and inconsistent results in the literature.
Some vasal injection and occlusion techniques described in the literature rely on chemicals or polymers that are not available for use in the United States. For example, certain sclerosing agents used in dye-confirmation techniques and the polymer styrene maleic anhydride (SMA) used in RISUG have been studied abroad but are not approved or available in U.S. practice; clinical trials are ongoing for some of these methods.
Orchiectomy is described in the evidence as a last‑resort option for patients with debilitating, refractory post‑vasectomy pain. The policy notes that despite being used as an extreme salvage measure, orchiectomy may be associated with a high rate of persistent pain in some series (for example, one study reported that 80% of patients continued to experience pain after orchiectomy), so it is not presented as a routinely effective solution.
The policy states that the procedures and surgical treatments listed as experimental and investigational — including endoscopic vasectomy, Vasclip, Pro‑Vas, vasal injection methods (e.g., RISUG), intra‑vas plugs, LigaSure occlusion, and surgical PVPS treatments such as epididymectomy and micro‑denervation of the spermatic cord — are considered investigational and are not supported as medically necessary because of inadequate evidence.
Endoscopic vasectomy and several novel endoluminal occlusion techniques remain investigational or preclinical. The available data are limited (often ex vivo or in small series, including porcine models and pilot device evaluations) and do not establish clinical utility or long‑term outcomes for these approaches.
Within the provided document excerpts there are no discrete scenarios explicitly labeled as “not medically necessary.” Instead, the policy frames certain procedures as investigational due to inadequate evidence and documents clinical pathways and criteria for medically necessary interventions (for example, vasectomy reversal for refractory post‑vasectomy pain).
Coding References
| 54860 | Epididymectomy; unilateral |
| 54861 | Epididymectomy; bilateral |
| 55400 | Vasovasostomy, vasovasorrhaphy |
| 55250 | Vasectomy, unilateral or bilateral (separate procedure), including postoperative semen examination(s) |
| 89310 | Semen analysis; motility and count (not including Huhner test) |
| 52402 | Cystourethroscopy with transurethral resection or incision of ejaculatory ducts |
| N50.81 | Testicular pain |
| Z30.2 | Encounter for sterilization |
| Z98.52 | Vasectomy status |
| G89.28 | Other chronic postprocedural pain [post-vasectomy] |
| No codes listed |
Provider Actions, Documentation & Prior Authorization
Verify prior authorization requirements for reversal-related procedures
Certain CPT codes related to vasectomy reversal and related procedures are described as covered when selection criteria are met; providers should verify whether prior authorization is required with the member's plan before scheduling (examples in the policy include CPT 54860, 54861, 55400).
No prior authorization statements present in this section
The policy text contains no explicit prior authorization statements for the procedures discussed; providers should not assume automatic authorization language is present in this section.
- The document states there are no prior authorization statements in this section
Prior authorization rules not specified in these sections
The policy chunks provided do not list specific CPT/HCPCS codes that universally require prior authorization or provide an explicit prior authorization ruleset; administrative verification is required per patient plan.
- Administrative note: check the member's benefit plan for any authorization triggers or local payer rules
Document prior conservative therapy before reversal
Conservative therapies (e.g., NSAIDs and local nerve blocks/steroid injections) are expected to be tried and documented and must have failed before vasectomy reversal is considered medically necessary for PVPS.
- Document trials of non-steroidal anti-inflammatory medications
- Document attempted local nerve blocks or steroid injections and clinical response
Escalate to surgery only after conservative management fails
For PVPS, initial management should be conservative or medical; surgical options (including vasectomy reversal, epididymectomy, or micro-denervation of the spermatic cord) are considered only after failure of conservative measures and exclusion of other causes.
- Ensure conservative/medical management has been attempted and failed before escalating to surgery
- Evaluate and rule out other causes of scrotal/testicular pain prior to surgical referral
Document conservative therapy attempted prior to surgery
Before proceeding to surgical treatment for PVPS, document use of noninvasive measures such as NSAIDs, warm baths, nerve blocks or steroid injections and their clinical outcomes.
- Record specific conservative modalities tried (NSAIDs, warm baths, nerve blocks/steroid injections)
- Record duration and response to each conservative therapy
Document failure of NSAIDs and local nerve interventions for VR necessity
Medical necessity documentation for vasectomy reversal for PVPS must show failure of NSAIDs and local nerve blocks/steroid injections.
- Include clinical notes documenting trial and failure of NSAIDs
- Include records of local nerve block or steroid injection attempts and outcomes
Vasal injection verification methods described in trials (research context)
In research descriptions of vasal injection techniques, procedural verification methods such as dye testing with urinary excretion to confirm placement/occlusion are described; note that some chemicals used in these techniques are not available in the U.S.
- Dye is injected into each vas with different colors and urinary excretion is observed to confirm occlusion
- Some required chemicals for certain sclerosing techniques are not available in the United States
Comprehensively document evaluation, counseling, and informed consent for VR in PVPS
When pursuing vasectomy reversal for PVPS, documentation should include prior conservative treatment attempts, evaluation to exclude other causes of scrotal/testicular pain, patient counseling about expected outcomes and alternative contraception, and informed consent describing potential for persistent pain and surgical risks.
- Document evaluation that rules out alternative sources of pain
- Document counseling on success rates, need for alternative contraception, and risk of persistent pain
Risk of denial for experimental/investigational procedures
Procedures listed in the policy as experimental or investigational (e.g., endoscopic vasectomy, Vasclip, Pro-Vas, RISUG, Intra Vas Plug, LigaSure, epididymectomy, micro-denervation of the spermatic cord) are considered investigational; use of these procedures may result in claim denial.
- Do not bill as medically necessary for indications listed as experimental/investigational in the policy
- Anticipate potential denial if these procedures are performed for covered indications
Limit routine opioid prescribing; document rationale if used
Routine opioid prescribing after vasectomy is associated with increased risk of new persistent opioid use and other adverse outcomes; providers should limit opioid prescriptions and document the rationale when opioids are used.
- Studies reported higher new persistent opioid use in opioid‑prescribed cohorts (e.g., 7.8% vs 1.5%)
- Document necessity when prescribing opioids and follow guideline-recommended opioid stewardship
Administrative metadata and review dates — verify plan rules
Policy administrative metadata and review history are provided (Effective 12/07/2004; Last review 03/06/2023; Next review 01/11/2024); these chunks do not specify explicit procedural prior authorization or denial triggers — verify current administrative rules with the payer.
- Effective date and review history are listed in the policy header
- Administrative metadata does not replace checking plan-specific authorization requirements
Background
Vasectomy is a common outpatient sterilization procedure in which the vas deferens are occluded to prevent sperm transport; techniques vary and include no‑scalpel approaches, excision with ligation/cautery, clips, and a range of device‑ or injection‑based occlusion methods. Failure rates are generally low (0–2%), complication rates are uncommon (<3%), and the procedure is performed frequently (approximately 500,000 procedures annually in the U.S.). A minority of men develop chronic post‑vasectomy pain—post‑vasectomy pain syndrome (PVPS)—which is managed initially with conservative measures (NSAIDs, warm baths, nerve blocks/steroid injections) and, when refractory and appropriately evaluated, may be considered for surgical interventions such as vasectomy reversal.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.